Phaseline

Companies › Apollomics

Apollomics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
APL-101
MET inhibitor
METPhase 2Solid Tumors; Metastatic Non Small Cell Lung CancerNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03175224APL-101Phase 2Solid TumorsOncologyNov 2026
NCT04743505APL-101Phase 1Metastatic Non Small Cell Lung CancerOncologyJan 2027

Targets

MET (1)

Companies with the same targets

AstraZeneca Johnson & Johnson (Janssen) Exelixis AbbVie Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Chia Tai Tianqing Pharmaceutical Group Beijing Scitech-Mq Pharmaceuticals IDEAYA Biosciences Shanghai Henlius Biotech DeuterOncology

Companies built like this

Abion Beijing Pearl Biotechnology Limited Liability Company Beijing Scitech-Mq Pharmaceuticals Shanghai Guangsheng Biopharmaceutical VIVUS

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.